Tag:

Affinivax

Latest Headlines

Latest Headlines

Affinivax nets another $2.5M from Gates Foundation to advance Prevnar competitor

February 5, 2016 | By
Cambridge, MA-based Affinivax launched in November 2014 with a $4 million Gates Foundation investment and plans to develop a pneumococcal vaccine that it believes could go beyond Prevnar, the best-selling vaccine in the world. Now, the biotech is announcing $2.5 million in follow-on funding from the Gates Foundation, which it will use to advance its lead candidate, CEO Steve Brugger told FierceVaccines.

Brand-new Affinivax takes aim at Pfizer's Prevnar with next-gen conjugate vax tech

October 30, 2014 | By
In conventional conjugate vaccines, proteins act as carriers for polysaccharides that induce an immune response. But what if those proteins could induce an immune response, too?
Related Tags
Press Releases
  • Philips Volcano announces more than 5,000 Coronary Artery Disease patients enrolled in iFR Outcomes Trials
  • Sun Pharma enters Japanese prescription market
  • Veracyte Secures Up to $45 Million in Financing from Visium Healthcare Partners
  • Merck Statement on hep C verdict
  • Quanterix Raises $46 Million in Series D Financing
  • More Press Releases
Sponsored Links